AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
-23.2%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.01B
AUM Growth
+$2.01B
(-30%)
Cap. Flow
+$140M
Cap. Flow
% of AUM
6.96%
Top 10 Holdings %
Top 10 Hldgs %
70.26%
Holding
110
New
9
Increased
21
Reduced
12
Closed
14
Top Buys
| 1 |
Moderna
MRNA
|
$80.3M |
| 2 |
Alibaba
BABA
|
$47.6M |
| 3 |
NIO
NIO
|
$26.1M |
| 4 |
Allogene Therapeutics
ALLO
|
$10.8M |
| 5 |
ARRY
Array Biopharma Inc
ARRY
|
$8.55M |
Top Sells
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$31.2M |
| 2 |
Amicus Therapeutics
FOLD
|
$9.58M |
| 3 |
AnaptysBio
ANAB
|
$9.57M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
$7.29M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$7.29M |
Sector Composition
| 1 | Healthcare | 65.65% |
| 2 | Consumer Discretionary | 33.07% |
| 3 | Real Estate | 0.37% |
| 4 | Communication Services | 0.16% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BOLD
26
DELISTED
Audentes Therapeutics, Inc
BOLD
| $12.8M | 0.47% | 600,000 +350,000 | +140% | +$7.46M |
|
|
ALBO
27
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $12.3M | 0.45% | 500,000 | – | – |
|
|
28
Allogene Therapeutics
ALLO
$251M
| $10.8M | 0.4% | +400,000 | New | +$10.8M |
|
29
Denali Therapeutics
DNLI
$2.23B
| $10.3M | 0.38% | 500,000 | – | – |
|
|
CMTA
30
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $10M | 0.37% | 850,000 +158,000 | +23% | +$1.86M |
|
|
SAGE
31
DELISTED
Sage Therapeutics
SAGE
| $9.58M | 0.35% | 100,000 | – | – |
|
|
32
AnaptysBio
ANAB
$569M
| $9.57M | 0.35% | 150,000 -150,000 | -50% | -$9.57M |
|
33
Madrigal Pharmaceuticals
MDGL
$9.76B
| $7.89M | 0.29% | 70,000 +20,000 | +40% | +$2.25M |
|
|
MDCO
34
DELISTED
Medicines Co
MDCO
| $7.66M | 0.28% | 400,000 | – | – |
|
35
VICI Properties
VICI
$36B
| $7.51M | 0.28% | +400,000 | New | +$7.51M |
|
|
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
| $7.29M | 0.27% | 200,000 -200,000 | -50% | -$7.29M |
|
37
Regenxbio
RGNX
$451M
| $7.13M | 0.26% | 170,000 +20,000 | +13% | +$839K |
|
38
AC Immune
ACIU
$205M
| $7.09M | 0.26% | 750,000 | – | – |
|
|
AGEN
39
Agenus
AGEN
$133M
| $6.55M | 0.24% | 2,750,000 | – | – |
|
40
Crinetics Pharmaceuticals
CRNX
$2.92B
| $6M | 0.22% | 200,000 | – | – |
|
41
Rocket Pharmaceuticals
RCKT
$354M
| $5.93M | 0.22% | 400,000 | – | – |
|
|
AXDX
42
DELISTED
Accelerate Diagnostics
AXDX
| $5.75M | 0.21% | 500,000 | – | – |
|
43
Krystal Biotech
KRYS
$4.27B
| $5.72M | 0.21% | 275,000 +125,000 | +83% | +$2.6M |
|
|
DRNA
44
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5.61M | 0.21% | 525,000 +100,000 | +24% | +$1.07M |
|
45
Sangamo Therapeutics
SGMO
$157M
| $4.59M | 0.17% | 400,000 +100,000 | +33% | +$1.15M |
|
46
Replimune Group
REPL
$422M
| $4.5M | 0.17% | 450,000 | – | – |
|
|
TBIO
47
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $4.5M | 0.17% | 600,000 | – | – |
|
48
Iovance Biotherapeutics
IOVA
$807M
| $4.43M | 0.16% | 500,000 -200,000 | -29% | -$1.77M |
|
49
CRISPR Therapeutics
CRSP
$4.71B
| $4.14M | 0.15% | 145,000 +45,000 | +45% | +$1.29M |
|
|
CBAY
50
DELISTED
Cymabay Therapeutics
CBAY
| $3.94M | 0.15% | 500,000 -300,000 | -38% | -$2.36M |
|